Table 1.
Major clinical trials of TCR-T cell therapies for solid tumor patients
| Disease | Antigen | HLA | TCR-T cell source | Clinical trial number | Phase | Status |
|---|---|---|---|---|---|---|
| Melanoma | MART-1 | HLA-A*02:01 | PB (patient) | NCT00910650 | II | Completed |
| MART-1 | HLA-A*02:01 | PB (patient) | NCT00509288 | II | Completed | |
| MAGE-A3 | HLA-DP*04:01/04:02 | PB (patient) | NCT02111850 | I/II | Completed | |
| MAGE-C2 | HLA-A*0201 | PB (patient) | NCT04729543 | I/II | Recruiting | |
| PRAME | HLA-A*02 | PB (patient) | NCT03686124 | I | Recruiting | |
| NY-ESO-1 | HLA-A*0201 | PB (patient) | NCT03638206 | I/II | Recruiting | |
| MAGE-A3/12 | HLA-A*02:01 | PB (patient) | NCT01273181 | I/II | Terminated | |
| NY-ESO-1 | HLA-A*02:01 | PB (patient) | NCT00670748 | II |
Terminated (A more highly selected protocol with ESO TCR opened for pts with melanoma) |
|
| gp 100 | HLA-A*02:01 | PB (patient) | NCT00509496 | II |
Terminated (Low accrual) |
|
| PRAME | HLA-A*02:01 | PB (patient) | NCT02743611 | I/II | Unknown | |
| Lung cancer | NY-ESO-1 | HLA-A*02 | PB (patient) | NCT02457650 | I | Unknown |
| NY-ESO-1/LAGE-1a | HLA-A*02:01 HLA-A*02:05 HLA-A*02 | PB (patient) | NCT03709706 | Ia/IIb | Active not recruiting | |
| Sarcoma | NY-ESO-1 | HLA-A*02 | PB (patient) | NCT01343043 | I | Completed |
| MAGE-A4c1032 | HLA-A*02 | PB (patient) | NCT03132922 | I | Active not recruiting | |
| Renal cell carcinoma | HERV-E | HLA-A*11:01 | CD8+/CD34+ T cell (patient) | NCT03354390 | I | Recruiting |
| TRAIL | / | PB (patient) | NCT00923390 | I/II | Terminated | |
| Bladder cancer | MAGE-A10c796 |
HLA-A*02:01 HLA-A*02:06 |
T cells (patient) | NCT02989064 | I | Completed |
| MAGE-A3 | HLA-A*01 | PB (patient) | NCT02153905 | I/II |
Terminated (Slow, insufficient accrual) |
|
| Esophageal cancer | MAGE-A4 | HLA-A*24:02 | Lymphocytes (patient) | UMIN000002395 | I | Completed |
| Metastatic cancer | CEA | HLA-A*02:01 | PB (patient) | NCT00923806 | I |
Terminated (Study was terminated due to poor accrual) |
| Pancreatic cancer | KRAS G12D | HLA-C*08:02 | TIL (patient) | NCT03935893 | II | Recruiting |
| Hepatocellular carcinoma | HBV |
HLA-A*02:01 HLA-Cw*08:01 |
PBMC (patient) | NCT03899415 | I | Recruiting |
| AFPc332 | HLA-A*02 | T cells (patient) | NCT03132792 | I | Recruiting | |
| HPV+ cancer | HPV-16 E6 | HLA-A*02 | PB (patient) | NCT02280811 | I/II | Completed |
| HPV-16 E7 | HLA-A*02 | PB (patient) | NCT02858310 | I/II | Recruiting |